Credit Suisse’s Orchestra BioMed OBIO Stock Holding History

Credit Suisse’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,341	Closed	-$93.4K	–	3166
2023 Q2	$93.4K	Buy	+13,341	New	+$202K	﹤0.01%	3134

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse's OBIO Position: Q3 2023 in Review

Credit Suisse sold out of Orchestra BioMed (OBIO) in Q3 2023, closing a stake of 13,341 shares — an estimated $93.4K sold.

Credit Suisse first reported a position in OBIO in Q2 2023 and held it in 1 quarter. The position peaked at $93.4K in Q2 2023. 42 funds tracked by Wall St. Rank hold OBIO as of Q3 2023.

Credit Suisse reported no remaining Orchestra BioMed position as of Q3 2023 after selling out during the quarter.
Credit Suisse sold 13,341 Orchestra BioMed shares in Q3 2023, an estimated $93.4K.
Credit Suisse first reported a position in Orchestra BioMed in Q2 2023 and held it in 1 quarter.
Credit Suisse's Orchestra BioMed position peaked at $93.4K in Q2 2023.
42 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.